

# Peter M Siegel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5061722/publications.pdf>

Version: 2024-02-01

94  
papers

14,166  
citations

66343

42  
h-index

43889

91  
g-index

97  
all docs

97  
docs citations

97  
times ranked

20980  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Genes that mediate breast cancer metastasis to lung. <i>Nature</i> , 2005, 436, 518-524.  | 27.8 | 2,581     |
| 2  | A multigenic program mediating breast cancer metastasis to bone. <i>Cancer Cell</i> , 2003, 3, 537-549.   | 16.8 | 2,325     |
| 3  | Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. <i>Nature</i> , 2012, 482, 226-231.  | 27.8 | 2,129     |
| 4  | AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo. <i>Cell Metabolism</i> , 2013, 17, 113-124.   | 16.2 | 754       |
| 5  | PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. <i>Cell Metabolism</i> , 2015, 22, 577-589.  | 16.2 | 430       |
| 6  | Transforming growth factor $\beta$ signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8430-8435. | 7.1  | 409       |
| 7  | Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. <i>EMBO Journal</i> , 1999, 18, 2149-2164.                        | 7.8  | 389       |
| 8  | Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. <i>Nature Genetics</i> , 2014, 46, 462-466.   | 21.4 | 381       |
| 9  | Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. <i>Oncogene</i> , 2018, 37, 3183-3199.  | 5.9  | 317       |
| 10 | Metabolic Plasticity as a Determinant of Tumor Growth and Metastasis. <i>Cancer Research</i> , 2016, 76, 5201-5208.   | 0.9  | 214       |
| 11 | Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. <i>Molecular and Cellular Biology</i> , 1994, 14, 7068-7077.  | 2.3  | 188       |
| 12 | PGC-1 $\alpha$ Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. <i>Cell Metabolism</i> , 2017, 26, 778-787.e5.   | 16.2 | 181       |
| 13 | Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2147-2156.   | 7.0  | 172       |
| 14 | Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. <i>Nature Genetics</i> , 2014, 46, 39-44.   | 21.4 | 167       |
| 15 | ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic Properties. <i>PLoS ONE</i> , 2010, 5, e12093.  | 2.5  | 149       |
| 16 | Osteoactivin Promotes Breast Cancer Metastasis to Bone. <i>Molecular Cancer Research</i> , 2007, 5, 1001-1014.  | 3.4  | 146       |
| 17 | Immature Low-Density Neutrophils Exhibit Metabolic Flexibility that Facilitates Breast Cancer Liver Metastasis. <i>Cell Reports</i> , 2019, 27, 3902-3915.e6.   | 6.4  | 144       |
| 18 | The role of claudins in cancer metastasis. <i>Oncogene</i> , 2017, 36, 1176-1190.   | 5.9  | 140       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. <i>Oncogene</i> , 2011, 30, 1318-1328.  | 5.9  | 130       |
| 20 | Novel Activating Mutations in the <i>neu</i> Proto-oncogene Involved in Induction of Mammary Tumors. <i>Molecular and Cellular Biology</i> , 1994, 14, 7068-7077.   | 2.3  | 124       |
| 21 | Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. <i>Breast Cancer Research</i> , 2015, 17, 45.  | 5.0  | 103       |
| 22 | Mammary tumors expressing the <i>neu</i> proto-oncogene possess elevated c-Src tyrosine kinase activity. <i>Molecular and Cellular Biology</i> , 1994, 14, 735-743.   | 2.3  | 96        |
| 23 | Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 839.  | 2.0  | 95        |
| 24 | Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3619-3625.   | 1.6  | 94        |
| 25 | Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 8878-8883. | 7.1  | 91        |
| 26 | Claudin-2 Promotes Breast Cancer Liver Metastasis by Facilitating Tumor Cell Interactions with Hepatocytes. <i>Molecular and Cellular Biology</i> , 2012, 32, 2979-2991.  | 2.3  | 89        |
| 27 | Mad Upregulation and Id2 Repression Accompany Transforming Growth Factor (TGF)- $\beta$ -mediated Epithelial Cell Growth Suppression. <i>Journal of Biological Chemistry</i> , 2003, 278, 35444-35450.  | 3.4  | 85        |
| 28 | Exosomal Release of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis. <i>Translational Oncology</i> , 2019, 12, 462-474.   | 3.7  | 66        |
| 29 | Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer. , 2017, 179, 127-141.  |      | 64        |
| 30 | Emerging therapeutic targets in breast cancer bone metastasis. <i>Future Oncology</i> , 2010, 6, 55-74.   | 2.4  | 63        |
| 31 | Signaling through ShcA Is Required for Transforming Growth Factor $\beta$ 2- and Neu/ErbB-2-Induced Breast Cancer Cell Motility and Invasion. <i>Molecular and Cellular Biology</i> , 2008, 28, 3162-3176.  | 2.3  | 61        |
| 32 | GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin $\alpha$ 5 $\beta$ 1 for efficient breast cancer metastasis. <i>Oncogene</i> , 2015, 34, 5494-5504.   | 5.9  | 61        |
| 33 | Translational and HIF-1 $\alpha$ -Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. <i>Cell Metabolism</i> , 2018, 28, 817-832.e8.   | 16.2 | 61        |
| 34 | Metabolic Profiles Associated With Metformin Efficacy in Cancer. <i>Frontiers in Endocrinology</i> , 2018, 9, 372.  | 3.5  | 61        |
| 35 | Creatine-mediated crosstalk between adipocytes and cancer cells regulates obesity-driven breast cancer. <i>Cell Metabolism</i> , 2021, 33, 499-512.e6.  | 16.2 | 61        |
| 36 | LPP is a Src substrate required for invadopodia formation and efficient breast cancer lung metastasis. <i>Nature Communications</i> , 2017, 8, 15059.   | 12.8 | 59        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. <i>Clinical Cancer Research</i> , 2018, 24, 6483-6494.  | 7.0  | 55        |
| 38 | CCN3 Impairs Osteoblast and Stimulates Osteoclast Differentiation to Favor Breast Cancer Metastasis to Bone. <i>American Journal of Pathology</i> , 2011, 178, 2377-2388.   | 3.8  | 54        |
| 39 | Chordin-Like 1 Suppresses Bone Morphogenetic Protein 4-Induced Breast Cancer Cell Migration and Invasion. <i>Molecular and Cellular Biology</i> , 2016, 36, 1509-1525.  | 2.3  | 53        |
| 40 | Optimizing live-cell fluorescence imaging conditions to minimize phototoxicity. <i>Journal of Cell Science</i> , 2020, 133, .   | 2.0  | 51        |
| 41 | Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis. <i>Oncotarget</i> , 2015, 6, 9476-9487.  | 1.8  | 47        |
| 42 | LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis. <i>Science</i> , 2018, 361, 406-411.   | 12.6 | 47        |
| 43 | Decreased PCSK9 expression in human hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2015, 15, 176.  | 2.0  | 46        |
| 44 | The influence of the pre-metastatic niche on breast cancer metastasis. <i>Cancer Letters</i> , 2016, 380, 281-288.  | 7.2  | 45        |
| 45 | Afadin cooperates with Claudin-2 to promote breast cancer metastasis. <i>Genes and Development</i> , 2019, 33, 180-193.   | 5.9  | 45        |
| 46 | LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. <i>Cancer &amp; Metabolism</i> , 2013, 1, 18.  | 5.0  | 44        |
| 47 | MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. <i>Clinical Cancer Research</i> , 2016, 22, 6088-6098.  | 7.0  | 43        |
| 48 | Mammary gland neoplasia: insights from transgenic mouse models. <i>BioEssays</i> , 2000, 22, 554-563.   | 2.5  | 40        |
| 49 | ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. <i>Breast Cancer Research</i> , 2012, 14, R149.  | 5.0  | 40        |
| 50 | Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation. <i>Bone</i> , 2008, 43, 386-393.   | 2.9  | 39        |
| 51 | Transcription factor regulatory networks in mammary epithelial development and tumorigenesis. <i>Oncogene</i> , 2010, 29, 2753-2759.  | 5.9  | 39        |
| 52 | Targeting tumor microenvironment in cancer therapy. <i>Cancer Letters</i> , 2016, 380, 203-204.   | 7.2  | 39        |
| 53 | A complex containing LPP and $\hat{\pm}$ -Actinin mediates TGF $\hat{\beta}$ <sup>2</sup> -induced migration and invasion of ErbB2-expressing breast cancer cells. <i>Journal of Cell Science</i> , 2013, 126, 1981-91. | 2.0  | 37        |
| 54 | The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 982-993.   | 4.1  | 34        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis. <i>Journal of Cell Communication and Signaling</i> , 2012, 6, 73-85.   | 3.4  | 33        |
| 56 | Peroxiredoxin 4: A novel secreted mediator of cancer induced osteoclastogenesis. <i>Cancer Letters</i> , 2015, 361, 262-270.   | 7.2  | 32        |
| 57 | Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern. <i>Communications Biology</i> , 2021, 4, 657.   | 4.4  | 32        |
| 58 | EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. <i>Oncogene</i> , 2018, 37, 4073-4093.  | 5.9  | 30        |
| 59 | Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. <i>British Journal of Cancer</i> , 2022, 127, 988-1013. | 6.4  | 30        |
| 60 | Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors. <i>Communications Biology</i> , 2020, 3, 310.                             | 4.4  | 28        |
| 61 | 5â€²-Inositol phosphatase SHIP2 recruits Mena to stabilize invadopodia for cancer cell invasion. <i>Journal of Cell Biology</i> , 2016, 214, 719-734.  | 5.2  | 27        |
| 62 | Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases. <i>Communications Biology</i> , 2021, 4, 950.  | 4.4  | 26        |
| 63 | Emerging roles for LPP in metastatic cancer progression. <i>Journal of Cell Communication and Signaling</i> , 2018, 12, 143-156.   | 3.4  | 25        |
| 64 | STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. <i>Nature Communications</i> , 2021, 12, 3299.                                    | 12.8 | 24        |
| 65 | Oncogenic Activating Mutations in the neu/erbB-2 Oncogene Are Involved in the Induction of Mammary Tumors. <i>Annals of the New York Academy of Sciences</i> , 1999, 889, 45-51.                               | 3.8  | 23        |
| 66 | A Three-Dimensional Dense Collagen Hydrogel to Model Cancer Cell/Osteoblast Interactions. <i>Journal of Functional Biomaterials</i> , 2018, 9, 72.   | 4.4  | 23        |
| 67 | Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion. <i>Breast Cancer Research</i> , 2018, 20, 9.   | 5.0  | 23        |
| 68 | Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer. <i>ELife</i> , 2021, 10, .  | 6.0  | 23        |
| 69 | The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L. <i>ELife</i> , 2016, 5, .  | 6.0  | 23        |
| 70 | GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and $\beta$ -catenin activity. <i>Oncogene</i> , 2019, 38, 5294-5307.                            | 5.9  | 22        |
| 71 | Neutrophils: Orchestrators of the Malignant Phenotype. <i>Frontiers in Immunology</i> , 2020, 11, 1778.  | 4.8  | 20        |
| 72 | C3a elicits unique migratory responses in immature low-density neutrophils. <i>Oncogene</i> , 2020, 39, 2612-2623.   | 5.9  | 20        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Distinct Phosphotyrosine-dependent Functions of the ShcA Adaptor Protein Are Required for Transforming Growth Factor $\beta^2$ (TGF $\beta^2$ )-induced Breast Cancer Cell Migration, Invasion, and Metastasis. <i>Journal of Biological Chemistry</i> , 2013, 288, 5210-5222. | 3.4 | 19        |
| 74 | CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro. <i>Scientific Reports</i> , 2019, 9, 16317.  | 3.3 | 19        |
| 75 | Invasive growth associated with cold-inducible RNA-binding protein expression drives recurrence of surgically resected brain metastases. <i>Neuro-Oncology</i> , 2021, 23, 1470-1480.  | 1.2 | 18        |
| 76 | High Throughput Traction Force Microscopy Using PDMS Reveals Dose-Dependent Effects of Transforming Growth Factor- $\beta$ on the Epithelial-to-Mesenchymal Transition. <i>Journal of Visualized Experiments</i> , 2019, , .   | 0.3 | 15        |
| 77 | Folliculin impairs breast tumor growth by repressing TFE3-dependent induction of the Warburg effect and angiogenesis. <i>Journal of Clinical Investigation</i> , 2021, 131, .  | 8.2 | 15        |
| 78 | The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers. <i>Cancers</i> , 2021, 13, 732.  | 3.7 | 14        |
| 79 | The ShcA PTB Domain Functions as a Biological Sensor of Phosphotyrosine Signaling during Breast Cancer Progression. <i>Cancer Research</i> , 2013, 73, 4521-4532.  | 0.9 | 13        |
| 80 | DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. <i>Anti-Cancer Drugs</i> , 2018, 29, 774-785.  | 1.4 | 12        |
| 81 | The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 1971-1990.   | 2.6 | 11        |
| 82 | p66ShcA functions as a contextual promoter of breast cancer metastasis. <i>Breast Cancer Research</i> , 2020, 22, 7.   | 5.0 | 10        |
| 83 | The SHCA adapter protein cooperates with lipoma-preferred partner in the regulation of adhesion dynamics and invadopodia formation. <i>Journal of Biological Chemistry</i> , 2020, 295, 10535-10559.   | 3.4 | 10        |
| 84 | Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. <i>Cell Reports</i> , 2022, 39, 110634.   | 6.4 | 10        |
| 85 | Future directions for bone metastasis research “ highlights from the 2015 bone and the Oncologist new updates conference (BONUS). <i>Journal of Bone Oncology</i> , 2016, 5, 57-62.  | 2.4 | 9         |
| 86 | Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration. <i>Journal of Bone Oncology</i> , 2017, 6, 8-15.  | 2.4 | 9         |
| 87 | CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis. <i>American Journal of Pathology</i> , 2019, 189, 1451-1461.   | 3.8 | 9         |
| 88 | Afadin (AF6) in cancer progression: A multidomain scaffold protein with complex and contradictory roles. <i>BioEssays</i> , 2021, 43, e2000221.  | 2.5 | 9         |
| 89 | HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin. <i>Oncogene</i> , 2022, 41, 1701-1717.   | 5.9 | 8         |
| 90 | GPNMB methylation: a new marker of potentially carcinogenic colon lesions. <i>BMC Cancer</i> , 2018, 18, 1068.   | 2.6 | 5         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 91 | A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC). <i>Journal of Clinical Oncology</i> , 2009, 27, 1067-1067. | 1.6 | 3         |
| 92 | Expanding the armamentarium for neutrophil-mediated angiogenesis. <i>Hepatology</i> , 2017, 65, 1796-1798.  | 7.3 | 1         |
| 93 | Abstract B056: Non-V600 BRAF mutations in melanoma: actionable targets for rational drug combinations. , 2018, , .  |     | 1         |
| 94 | Featuring the guest editors: Special issue tumor microenvironment. <i>Cancer Letters</i> , 2016, 380, 201-202.  | 7.2 | 0         |